Key result
SC-49992 prevented occlusive thrombus formation in a dose-dependent manner (0% at 60 mcg/kg/min vs 100% for control; p<0.05) and prevented rethrombosis after thrombolysis in a canine model.
Why the study?
Does SC-49992 prevent thrombosis and rethrombosis in a canine model of carotid artery thrombosis?
Population
Anaesthetised dogs in a canine model of carotid artery thrombosis (n=36)
Comparison
SC-49992 30 or 60 micrograms/kg/min… vs Saline infusion
Design
Preclinical
Follow-up
240 minutes
Authors
Loading...
Supports antithrombotic development in canines; leaves open translation to human arterial thrombosis.
Does SC-49992 prevent thrombosis and rethrombosis in a canine model of carotid artery thrombosis?
Absolute Event Rate: 0% vs 100%
p-value: p=< 0.05
SC-49992, a GPIIb/IIIa receptor antagonist, effectively prevents arterial thrombosis and rethrombosis after thrombolysis in a canine model.
Rote et al. (1993) studied Arterial thrombosis (n=36). SC-49992 vs. Saline was evaluated on Frequency of occlusive thrombus formation (p=< 0.05). SC-49992 prevented occlusive thrombus formation in a dose-dependent manner (0% at 60 mcg/kg/min vs 100% for control; p<0.05) and prevented rethrombosis after thrombolysis in a canine model.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: